NL-OMON24500招募中不适用
Integrated Biomarker and Imaging Study: To Assess the Ability of Rosuvastatin to Decrease Necrotic Core in Coronary Arteries.
Erasmus Medical center (Thoraxcenter)0 个研究点目标入组 300 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 300
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. More than 18 years old;
- •2. Written informed consent;
排除标准
- •1. Braunwald class IA, IIA, IIIA (unstable angina caused by non-cardiac illness);
- •2. Women who are pregnant or women of childbearing potential who do not use adequate contraception;
研究者
相似试验
进行中（未招募）
不适用
Integrated Biomarker and Imaging Study – 2 (IBIS-2) - IBIS-2EUCTR2005-001556-20-CZGlaxoSmithKline Research & Development Limited300
进行中（未招募）
1 期
Integrated Biomarker and Imaging Study – 2 (IBIS-2)Estudio integrado de biomarcadores y técnicas de imagen - 2 (IBIS-2) - IBIS-2EUCTR2005-001556-20-ESGlaxoSmithKline, S.A.
进行中（未招募）
不适用
Integrated Biomarker and Imaging Study – 2 (IBIS-2) - IBIS-2EUCTR2005-001556-20-ATGlaxoSmithKline Research & Development Limited300
进行中（未招募）
1 期
Integrated Biomarker and Imaging Study – 2 (IBIS-2) - IBIS-2SB-480848 is under developement as a potential anti-atherosclerosis agent for reduction of major cardiovascular events in high risk patient populations.EUCTR2005-001556-20-GBGlaxoSmithKline Research & Development Limited
进行中（未招募）
不适用
Integrated Biomarker and Imaging Study – 2 (IBIS-2) - IBIS-2SB-480848 is under developement as a potential anti-atherosclerosis agent for reduction of major cardiovascular events in high risk patient populations.EUCTR2005-001556-20-DKGlaxoSmithKline Research & Development Limited300